222. Current Management of Ankylosing Spondylitis in the UK: The Patient Perspective

Abstract

3rd TNFi drug and 2 switching to a 4th TNFi drug. Secondary failure was the main cause of switching, with 26 switching for this reason after the first TNFi (mean duration 28 months). Adverse events were the cause of switching in 6 patients receiving the first TNFi. Primary failure (mean duration 5 months) was the reason in 4 patients receiving their first TNFi. Responses to the first switch were that 25/39 (64%) continued on the second TNFi (mean duration on therapy of 43 months). Of the 14 patients who subsequently switched to a 3rd TNFi therapy, 9 had secondary failure (mean duration 14 months on 2nd TNFi), 2 had primary failure and 3 had adverse events. 10/14 (71%) patients continue on a 3rd TNFi, with 3 switched due to secondary failure and 1 primary failure. 3 patients received and responded to a 4th TNFi drug. Conclusion: These data support previous studies that people with PsA receiving TNFi therapy have a lower rate of secondary failure to TNFi therapy compared with RA. Our data show that after switching most people remain on the second TNFi for a substantial time, suggesting efficacy is maintained. Disclosure statement: L.B. has received honoraria from Roche, MSD, Pfizer and BMS. B.K. has received honoraria from AbbVie, BMS, MSD, Novartis, Pfizer, Roche and UCB. S.M. has received honoraria from BMS.